

Interleukin-6 and intrapulmonary shunt

Copyright ©The authors 2021.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 5 May 2021 Accepted: 6 June 2021







To the Editor:

We read with interest the article by Kotwica *et al.* [1] showing the utility of clinical pulse oximetry measurements to quantify shunt and ventilation—perfusion mismatch and their predictive value in severe coronavirus disease 2019 (COVID-19). The authors found that shunt correlated with markers of activated inflammatory response (*i.e.* C-reactive protein) but not those of activated coagulation (such as D-dimer). Their results reinforce the growing evidence for the role of impaired hypoxic pulmonary vasoconstriction (HPV) as a primary cause for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced hypoxaemia [2].

We would like to draw the attention of readers to a possible pathophysiological role of interleukin (IL)-6 in intrapulmonary shunt associated with SARS-CoV-2-induced acute respiratory distress syndrome that has been overlooked. IL-6 is a fundamental player in the inflammation associated with COVID-19 and the level of this cytokine serves as a biomarker of poor prognosis [3]. Moreover, although controversy remains regarding the population of patients that may benefit from anti-IL-6 therapies in COVID-19, two large randomised clinical trials have shown reduced mortality in patients treated with tocilizumab [4, 5], and seven randomised controlled trials have shown reduced risk of mechanical ventilation [6].

The initial evidence for the involvement of IL-6 in impaired HPV comes from studies in mice and rats. Thus, human recombinant IL-6 inhibited HPV in mice [7]. We also observed that IL-6 inhibited HPV and an antibody against IL-6 prevented the impairment of HPV induced by bacterial endotoxin in isolated rat pulmonary arteries [8]. In addition, several studies have demonstrated a positive impact of tocilizumab on arterial oxygenation in patients with severe COVID-19 [9, 10].

In conclusion, we speculate that IL-6 is involved in the impaired HPV associated with COVID-19. The relationship of intrapulmonary shunt with IL-6 levels and with anti-IL-6 therapies deserves further investigation.

Shareable abstract (@ERSpublications)

Based on animal studies and indirect clinical evidence, it may be speculated that IL-6 has a pathophysiological role in intrapulmonary shunt associated to COVID-19 https://bit.ly/3whQVqd

Cite this article as: Perez-Vizcaino F, Moreno L, Lorente JA. Interleukin-6 and intrapulmonary shunt. Eur Respir J 2021; 58: 2101292 [DOI: 10.1183/13993003.01292-2021].

Francisco Perez-Vizcaino^{1,2,3}, Laura Moreno^{1,2,3} and José A. Lorente^{2,4,5}

¹Dept of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. ²CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. ³Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain. ⁴Critical Care Service, Hospital Universitario de Getafe, Madrid, Spain. ⁵Universidad Europea, Madrid, Spain.

Corresponding author: Francisco Perez-Vizcaino (fperez@med.ucm.es)

Conflict of interest: F. Perez-Vizcaino reports fees for lectures from Actelion. L. Moreno has nothing to disclose. J.A. Lorente has nothing to disclose.

References

- 1 Kotwica A, Knights H, Mayor N, *et al.* Intrapulmonary shunt measured by bedside pulse oximetry predicts worse outcomes in severe COVID-19. *Eur Respir J* 2021; 57: 2003841.
- 2 Habashi NM, Camporota L, Gatto LA, et al. Functional pathophysiology of SARS-CoV-2-induced acute lung injury and clinical implications. J Appl Physiol (1985) 2021; 130: 877–891.

- 3 Sayah W, Berkane I, Guermache I, *et al.* Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19. *Cytokine* 2021; 141: 155428.
- 4 Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021; 397: 1637–1645.
- 5 Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021; 384: 1491–1502.
- 6 Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect 2021; 27: 215–227.
- 7 Voiriot G, Razazi K, Amsellem V, *et al.* Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury. *Respir Res* 2017; 18: 64.
- 8 Pandolfi R, Barreira B, Moreno E, *et al.* Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction. *Thorax* 2017; 72: 460–471.
- 9 Wang D, Fu B, Peng Z, et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med 2021; 15: 486–494.
- 10 Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117: 10970–10975.